Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkEffect of Postreinduction Therapy Consolidation w. Blinatumomab vs. Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults w. First Relapse of B-Cell ALL

In this Original Investigation from JAMA, the authors discuss the results of a randomized clinical trial that included 208 patients with high- and intermediate-risk first relapse of B-cell acute lymphoblastic leukemia (ALL). Did postreinduction treatment with blinatumomab compared with chemotherapy, followed by hematopoietic stem cell transplant, result in a statistically significant difference in disease-free survival?

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form